Hemostatic characteristics of thawed, pooled cryoprecipitate stored for 35 days at refrigerated and room temperatures.


Journal

Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360

Informations de publication

Date de publication:
04 2019
Historique:
received: 24 11 2018
revised: 09 01 2019
accepted: 09 01 2019
entrez: 14 4 2019
pubmed: 14 4 2019
medline: 27 8 2019
Statut: ppublish

Résumé

Cryoprecipitate's shelf life is limited due to concerns over decreased clotting factor activity and contamination with extended storage. Hemostatic characteristics of thawed cryoprecipitate stored up to 35 days at refrigerated and room temperatures were assessed. Pooled cryoprecipitate was thawed and aliquoted for storage at 1-6°C or 21-24°C. Samples were tested immediately after thawing and at 4 h, 24 h, 72 h, and weekly for 35 days. At each time point fibrinogen, factor VIII (FVIII), and von Willebrand factor (vWF) were assessed. Thrombin generation and rotational thromboelastometry (ROTEM) were also performed. Further, packed red cells, platelet concentrates, frozen plasma, and stored cryoprecipitate were combined (1:1:1:1) to simulate massive transfusion and analyzed by ROTEM. Day 35 samples were cultured for bacterial contamination. Precipitation was observed in refrigerated samples; however, these aggregates were easily resuspended upon warming in a 37°C water bath. No significant changes were observed in fibrinogen concentration or ROTEM at either temperature. FVIII and vWF declined significantly during storage. vWF, clot time, and thrombin generation were significantly better preserved with refrigeration. With simulated massive transfusion, fibrinogen function remained at or above the established range for whole blood at both storage temperatures. Bacterial contamination was not observed in cold stored or room temperature cryoprecipitate. The fibrinogen concentration and function of cryoprecipitate at extended storage durations are adequate for fibrinogen replacement in critical bleeding. These results support extension of the shelf life of cryoprecipitate when used for fibrinogen replacement.

Sections du résumé

BACKGROUND
Cryoprecipitate's shelf life is limited due to concerns over decreased clotting factor activity and contamination with extended storage. Hemostatic characteristics of thawed cryoprecipitate stored up to 35 days at refrigerated and room temperatures were assessed.
STUDY DESIGN AND METHODS
Pooled cryoprecipitate was thawed and aliquoted for storage at 1-6°C or 21-24°C. Samples were tested immediately after thawing and at 4 h, 24 h, 72 h, and weekly for 35 days. At each time point fibrinogen, factor VIII (FVIII), and von Willebrand factor (vWF) were assessed. Thrombin generation and rotational thromboelastometry (ROTEM) were also performed. Further, packed red cells, platelet concentrates, frozen plasma, and stored cryoprecipitate were combined (1:1:1:1) to simulate massive transfusion and analyzed by ROTEM. Day 35 samples were cultured for bacterial contamination.
RESULTS
Precipitation was observed in refrigerated samples; however, these aggregates were easily resuspended upon warming in a 37°C water bath. No significant changes were observed in fibrinogen concentration or ROTEM at either temperature. FVIII and vWF declined significantly during storage. vWF, clot time, and thrombin generation were significantly better preserved with refrigeration. With simulated massive transfusion, fibrinogen function remained at or above the established range for whole blood at both storage temperatures. Bacterial contamination was not observed in cold stored or room temperature cryoprecipitate.
CONCLUSION
The fibrinogen concentration and function of cryoprecipitate at extended storage durations are adequate for fibrinogen replacement in critical bleeding. These results support extension of the shelf life of cryoprecipitate when used for fibrinogen replacement.

Identifiants

pubmed: 30980741
doi: 10.1111/trf.15180
doi:

Substances chimiques

Hemostatics 0
cryoprecipitate coagulum 0
von Willebrand Factor 0
F8 protein, human 839MOZ74GK
Factor VIII 9001-27-8
Fibrinogen 9001-32-5
Thrombin EC 3.4.21.5

Types de publication

Journal Article

Langues

eng

Pagination

1560-1567

Informations de copyright

© 2019 AABB.

Auteurs

Joshua L Fenderson (JL)

Blood Research Program, US Army Institute of Surgical Research, Fort Sam Houston, Texas.

M Adam Meledeo (MA)

Blood Research Program, US Army Institute of Surgical Research, Fort Sam Houston, Texas.

Matthew J Rendo (MJ)

Blood Research Program, US Army Institute of Surgical Research, Fort Sam Houston, Texas.

Grantham C Peltier (GC)

Blood Research Program, US Army Institute of Surgical Research, Fort Sam Houston, Texas.

Colby S McIntosh (CS)

Blood Research Program, US Army Institute of Surgical Research, Fort Sam Houston, Texas.

Kenneth W Davis (KW)

Blood Research Program, US Army Institute of Surgical Research, Fort Sam Houston, Texas.

Jason B Corley (JB)

Blood Research Program, US Army Institute of Surgical Research, Fort Sam Houston, Texas.

Andrew P Cap (AP)

Blood Research Program, US Army Institute of Surgical Research, Fort Sam Houston, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH